of the amino acid. Suitable amino acids include both natural and non-natural amino acids. The composition

COMPOSITION FOR PREVENTING OR TREATING ASTHMA, RHINITIS OR CONJUNCTIVITIS, COMPRISING N-ACYL AMINO ACID AS ACTIVE INGREDIENT - Patent application

pH), aliphatic amino acids, with similar pK.sub.a-values: TABLE -US-00001 Basic amino acid L-lysine L

1-10, wherein the anti-CD33 antibody binds to one or more amino acids within amino acid

was used for synthesis of all the peptides. All Fmoc amino acids were activated by

and 200 amino acid residues in length, and wherein the amino acid sequence X1-C

of the amino acid is selected from the twenty kinds of amino acids consisting of

of the amino acid is selected from the twenty kinds of amino acids consisting of

A) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth

sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is

CDR2, and a VL-CDR3; wherein the VH-CDR3 comprises an amino acid sequence selected from

the BTB domain of claim 1 linked to a heterologous amino acid sequence. 3. The

2S)-2-amino-3-methylbutanoate, or a pharmaceutically acceptable salt thereof. 4. (5-{3-Amino-5-[4-(trifluoromethoxy)benzene

amino acid; a glycosylated or carbohydrate modified amino acid; a keto containing amino acid; amino acids comprising

some cases, the amino acid substitution at position 322 or the homologous amino acid position is a

to novel 4-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels

method of claim 262, wherein isolating single fetal.cells is carried out by fluorescence activated cell sorting (FACS). 264

amino acid may be a natural amino acid or a non-natural amino acid. In one

or primary amino (--NH.sub.2) groups that readily form covalent linkages, preferably amide bonds, with activated carbonyl groups (e.g. acyl

at least one amino acid of the peptide is a D-amino acid. 19. The

a full-length TREM1 amino acid sequence, preferably a polypeptide having 50-85 amino acids of the

the second extracellular region peptide each contain at least a part of amino acid sequence of

with the amino acid sequence shown in SEQ ID No: 10; (ii) an amino acid sequence having a

1 with one or more amino acid modifications, and VL comprising the amino acid sequence of

sequence with at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with an amino acid sequence shown in

corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine

8 amino acids, at least 9 amino acids, at least 10 amino acids, at least 11 amino acids, or at least

an amino acid sequence as shown in SEQ ID NO: 9 (GGQNNGYDL). [0104] "Percent (%) amino acid sequence identity" with

support following an amino acid sequence with at least 60% identity to the amino acid sequence set forth

has cancer, comprising administering to said patient a population of activated T cells that kill

terminated with: i) a functional group selected from amine, carbamate, carboxylic acid, carboxylate, maleimide, activated ester, N-hydroxysuccinimidyl, hydrazine

1, the amino acid sequence of SEQ ID NO:5, the amino acid sequence of

doping and activation of the crosslinker. The crosslinkers can be activated thermally, by UV radiation

more non-natural amino acid residues (such as replacement of one or more polar amino acid residues with one

natural or non-natural amino acid, that is an alkanoic acid derivative having at least one amino group as a

a test protein, wherein the peptide is between about 7 and 110 amino acids in length

chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-- 5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]met- hyl

thermal process is between 120° C. and 150° C. 2022-07-28 20220235518 LAUNDERABLE ACTIVATED COTTON - An activated cotton

capable of binding to T cell epitopes in the amino acid sequence of

a heavy-chain variable region containing a heavy-chain CDR1 containing the amino acid sequence represented by

pathways including the PI3K pathway and the Akt pathway are weakly activated in human

occurring microbial organism of claim 46, wherein the aldehyde dehydrogenase comprises an amino acid sequence having at

the HLA-DR beta chain; wherein the CII peptide comprises the amino acid sequence selected from

from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino

the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the

nuclease; (ii) an amino acid sequence encoding a linker; and (iii) an amino acid sequence encoding a

3; (b) a protein consisting of an amino acid sequence having an amino acid sequence identity of

18, wherein the compound is: 1-[4-[6-[5-[(6-tert-butoxypyrazin-2-yl)amino]-1-methyl-pyrazol-4

list of abbreviations, letters, characters or words representing amino acid residues. The amino acid abbreviations used herein

replacement of one amino acid at a given position or residue by another amino acid at the

of a neuraminidase inhibitor, sodium chloride, a buffer and, an amino acid wherein the

or p-acetyl-phenylalanine, amino acid bearing a .beta.-diketone side chain, (S)-2-amino-6-(((1R,2R)-2

the cell growth of cancer cell lines in which RON is activated, but also can effectively

a bodily tissue or a thermally-driven reaction or a catalytically-activated reaction. 7. The

1-R.sup.14 are each independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, amino, substituted amino, carboxyl, substituted

a pre-determined location in the microarray and comprising an amino acid sequence of

08 Patent application number: 20220280581 Abstract: The combination of specific immunoglobulins plus activated Bifidobacteria strains or other

which is different from a tyrosine residue, said amino acid residue preferably bearing an amino group chemically modified with

the present inventors have clarified by analysis using hM4Di, which is an inhibitory designer receptor exclusively activated by designer drug (DREADD

sub.w, wherein z is an integer from 1 to 100; X is any amino acid, and w

1, LCDR2 has an amino acid sequence given by SEQ ID NO: 2, LCDR3 has an amino acid sequence given by

with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl

W32 of GDF-15 (SEQ ID NO: 485), an amino acid in amino acids V33-Q40 of

include or exclude one or more non-natural, chemically or otherwise modified amino acids, or non-amino acid moieties. A

2-y- l)-4-((2-oxido-4-(pyridin-4-yl)-1,3,2-dioxaphosphinan-2-yl)amino)pyrimidin- -2(1H)-one

exchange. [0026] Calcium accumulates inside the cell activating intracellular cytotoxic processes. Microglial cells are activated and release

conservative" amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to

8 to about 18 amino acids, from about 8 to about 16 amino acids, from about 8

wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which

comprising the amino acid sequence ATNFSLLKQAGDVEENPGP (SEQ ID NO: 6); E2A, comprising the amino acid sequence QCTNYALLKLAGDVESNPGP (SEQ

alpha.-amino butyric acid, L-.gamma.-amino butyric acid, L-.alpha.-amino isobutyric acid, L-.epsilon.-amino caproic acid, 7-amino

can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides

comparing them with corresponding reference indicators: (1) relative abundance of gut microbes; (2) an amino acid level; (3) a

at wherein amino acid modifications are made at one or more of the amino acids within the

known that TGF-.beta. has five isoforms having 70-80% homology in the amino acid sequence, and

delivery and expression system according to claim 1, wherein the amino acid sequence of

targeted agents, particularly those interfering with signal transduction (e.g., epidermal growth factor receptor [EGFR] inhibitors, mitogen activated protein kinase kinase [MEK

is optionally substituted with halogen, amino, nitro, cyano; C6-C10 aryl, optionally substituted by halogen, nitro, amino, hydroxy, cyano; C3-C6

capable of binding to T cell epitopes in the amino acid sequence of

SYSTEM AND METHOD - A self-contained system for medication injection is activated by the user

natural and synthetic amino acids, and both D and L amino acids. "Standard amino acid

marker may be activated by a ligand reaction. The marker may be activated by interaction with a

the cell growth of cancer cell lines in which RON is activated, but also can effectively

IL-6 induces B-cell proliferation, antibody secretion, and survival of plasmablasts. Activated B cells produce IL

17. The method of claim 15, wherein the mutation is at amino acid position K4, Y69

adoptive cell therapy. 2. The method according to claim 1, wherein fluorescence-activated cell sorting (FACS) is

of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from

is higher than an amino acid concentration of the first medium; e.g., an amino acid concentration above a

of nitric oxide when and where it is needed, using the amino acid arginine as the

covalently attached to the support matrix. For example, agarose beads are activated using cyanogen bromide or

monocyte is selected from the group consisting of a macrophage, an activated macrophage, a monocyte

of claim 102, wherein the CsgGE export signal sequence comprises the amino acid sequence of

administration of the candidate horse IL-31 inhibitor. 2022-09-01 20220273794 CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS - The

of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Amino acids

3 are independently selected from the group consisting of H, cyano, hydroxyl, amino, acetamido, halo, alkoxy, nitro

a plant, comprising over-expressing within the plant a polypeptide comprising an amino acid sequence having at

a plant, comprising over-expressing within the plant a polypeptide comprising an amino acid sequence having at

the implants cause inflammation and increase the number of activated macrophages and the

or one or more N-terminal amino acid and one or more C-terminal amino acid relative to

present invention relates to components, systems, and methods for identifying amino acid glycosylation tag motifs